Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | PPARA | Q07869 | 4/20 | 0.58 |
| ▸ | PPARG | P37231 | 3/20 | 0.58 |
| ▸ | PPARD | Q03181 | 3/20 | 0.53 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.52 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.52 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1206101 | 0.93 | PPARA (0.64) | LMNAL3MBTL1FFAR1PPARAPPARG | |
| SCHEMBL17345292 | 0.90 | PPARA (0.69) | FFAR1PPARAPPARGPLA2G4B | |
| SCHEMBL25456542 | 0.90 | PPARA (0.69) | FFAR1PPARAPPARGPLA2G4B | |
| Phenyl Propionic Acid SCHEMBL28543757 | 0.90 | LMNA (0.59) | LMNAL3MBTL1FFAR1KMT2APPARA | |
| SCHEMBL22526149 | 0.88 | KMT2A (0.55) | LMNAL3MBTL1FFAR1KMT2APPARA | |
| SCHEMBL22525373 | 0.88 | KMT2A (0.55) | LMNAL3MBTL1FFAR1KMT2APPARA | |
| SCHEMBL1205963 | 0.88 | FFAR1 (0.61) | FFAR1PPARAPPARGPPARDFFAR4 | |
| Phenyl Propionic Acid SCHEMBL1868194 | 0.88 | LMNA (0.82) | LMNAL3MBTL1FFAR1FFAR4PLA2G4A | |
| SCHEMBL3668051 | 0.87 | FFAR1 (0.60) | LMNAL3MBTL1FFAR1PPARAPPARG | |
| SCHEMBL3209970 | 0.86 | CYP2D6 (0.59) | LMNAL3MBTL1KMT2APPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| US-11253596-B2 | Phenylalkylcarboxylic acid delivery agents | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2022-02-22 | — | — | US | claimed |
| US-20200405863-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | NOVO NORDISK A/S (DK) | 2020-12-31 | — | — | US | claimed |
| EP-2114145-B1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | EMISPHERE TECH INC (US) | 2017-11-01 | — | — | EP | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| US-20120258911-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2012-10-11 | — | — | US | claimed |
| US-20110046050-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-02-24 | — | — | US | claimed |
| EP-2114145-A2 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | Emisphere Technologies, Inc. (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2008112368-A2 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-09-18 | — | — | WO | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | disclosed |
| US-11253596-B2 | Phenylalkylcarboxylic acid delivery agents | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2022-02-22 | — | — | US | disclosed |
| US-20200405863-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | NOVO NORDISK A/S (DK) | 2020-12-31 | — | — | US | disclosed |
| US-10456472-B2 | Phenylalkylcarboxylic acid delivery agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| EP-2114145-A2 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | Emisphere Technologies, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008112368-A2 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112368-A2 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | BIEDIGER RONALD J | 2006-12-07 | — | — | US | disclosed |
| US-6972296-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, ITGA1 | LMNA 1820/4885L3MBTL1 3947/4885FFAR1 74/4885 |
| US-20200405863-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | PGF, LIPA, PDGFA | LMNA 868/4885L3MBTL1 2214/4885FFAR1 713/4885 |
| US-10456472-B2 | Phenylalkylcarboxylic acid delivery agents | PGF, LIPA, PDGFA | LMNA 868/4885L3MBTL1 2214/4885FFAR1 713/4885 |
| US-20110046050-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | PGF, LIPA, PDGFA | LMNA 868/4885L3MBTL1 2214/4885FFAR1 713/4885 |
| US-11253596-B2 | Phenylalkylcarboxylic acid delivery agents | PGF, LIPA, PDGFA | LMNA 868/4885L3MBTL1 2214/4885FFAR1 713/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | LMNA 4376/4885L3MBTL1 4673/4885FFAR1 2107/4885 |
| US-20120258911-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | PGF, LIPA, PDGFA | LMNA 868/4885L3MBTL1 2214/4885FFAR1 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.